Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2023 16:05 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
October 31, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
October 05, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
September 19, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency...
September 05, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
August 10, 2023 16:01 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today,...
August 03, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023

BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
August 01, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
July 19, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
June 23, 2023 08:00 ET | Source: scPharmaceuticals, Inc.

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...